Strategic injectrode Target medical device buyers and neuromodulation suppliers with Neuronoff’s Injectrode platform for minimally invasive peripheral nerve stimulation that avoids surgery and opioids, highlighting a compelling alternative in chronic pain management.

Clinical validation Leverage recent large animal demonstration and IPG compatibility milestones to engage researchers and procurement teams at academic medical centers and hospitals pursuing translational neuromodulation therapies and scalable implantable solutions.

Funding momentum Position as a growth partner to investors and grant programs by emphasizing ongoing financing rounds and NIH grant history, signaling de-risked early-stage commercialization potential for strategic collaborations and co-development deals.

Strategic fit buyers Identify mid to large medical device companies with neuromodulation portfolios that could integrate Injectrode technology or co-develop next-generation pain management devices, expanding product lines without full redevelopment.

Market timing Capitalize on the chronic pain and neuromodulation market trend by offering a ready-to-integrate platform that reduces surgical risk and opioid dependency, appealing to hospitals and pain clinics seeking safer, minimally invasive options.